Ruat M, Traiffort E, Bouthenet M L, Schwartz J C, Hirschfeld J, Buschauer A, Schunack W
Unité de Neurobiologie et Pharmacologie (U. 109), l'Institut National de la Santé et de la Recherche, Paris, France.
Proc Natl Acad Sci U S A. 1990 Mar;87(5):1658-62. doi: 10.1073/pnas.87.5.1658.
Iodoaminopotentidine (I-APT)--i.e., N-[2-(4-amino-3-iodobenzamido)ethyl]-N'-cyano-N''-(3-[3- (1-piperidinylmethyl)phenoxy]propyl)guanidine--represents one of the most potent H2-receptor antagonists known so far. In membranes of guinea pig brain 125I-APT bound reversibly, selectively, and with high affinity (Kd = 0.3 nM) to a homogeneous population of sites unambiguously identified as H2 receptors by inhibition studies conducted with a large panel of antagonists. 125I-APT binding was also inhibited by histamine, and the effect was modulated by a guanyl nucleotide, which is consistent with the association of the H2 receptor with a guanine nucleotide binding regulatory protein. The low nonspecific binding of 125I-APT generated high contrast autoradiographic pictures in brain sections and established the precise distribution of H2 receptors. Their highly heterogeneous distribution and laminated pattern in some areas--e.g., cerebral and hippocampal cortices--suggest their major association with neuronal elements. These localizations were more consistent than those of H1 receptors with the distribution of histaminergic projections, indicating that H2 receptors mediate a larger number of postsynaptic actions of histamine--e.g., in striatum. Colocalizations of H1 and H2 receptors in some areas account for their known synergistic interactions in cAMP formation induced by histamine. The distribution of 125I-APT binding sites did not strictly parallel that of the H2-receptor-linked adenylate cyclase activity, which may reflect heterogeneity among H2 receptors. After UV irradiation and SDS/PAGE analysis, [125I]iodoazidopotentidine (125I-AZPT), a photoaffinity probe derived from 125I-APT, was covalently incorporated in several peptides, among which the labeling of two peptides of 59 and 32 kDa was prevented by H2 antagonists, suggesting that they correspond to H2-receptor binding peptides or proteolysis products of the latter. These probes should be useful for sensitive radioassays, localization, purification, and molecular studies of the H2 receptor, which were previously impracticable.
碘胺泊替定(I-APT),即N-[2-(4-氨基-3-碘苯甲酰胺基)乙基]-N'-氰基-N''-(3-[3-(1-哌啶基甲基)苯氧基]丙基)胍,是目前已知的最强效H2受体拮抗剂之一。在豚鼠脑细胞膜中,125I-APT可逆、选择性且高亲和力(Kd = 0.3 nM)地结合到一组明确鉴定为H2受体的同质位点上,这是通过用大量拮抗剂进行抑制研究得出的结论。组胺也能抑制125I-APT的结合,且这种效应受鸟苷酸调节,这与H2受体与鸟嘌呤核苷酸结合调节蛋白的关联一致。125I-APT的低非特异性结合在脑切片中产生了高对比度的放射自显影片,并确定了H2受体的精确分布。它们在某些区域,如大脑皮质和海马皮质,高度异质的分布和分层模式表明它们主要与神经元成分相关。这些定位比H1受体的定位与组胺能投射的分布更一致,表明H2受体介导了组胺的大量突触后作用,如在纹状体中。H1和H2受体在某些区域的共定位解释了它们在组胺诱导的cAMP形成中已知的协同相互作用。125I-APT结合位点的分布与H2受体相关的腺苷酸环化酶活性的分布并不严格平行,这可能反映了H2受体之间的异质性。紫外线照射和SDS/PAGE分析后,[125I]碘叠氮泊替定(125I-AZPT),一种由125I-APT衍生的光亲和探针,共价结合到几种肽中,其中59 kDa和32 kDa的两种肽的标记被H2拮抗剂阻止,表明它们对应于H2受体结合肽或后者的蛋白水解产物。这些探针对于H2受体的灵敏放射测定、定位、纯化和分子研究应该是有用的,而这些研究以前是不可行的。